The year has also provided us with more information about how best to manage myocardial infarction beyond door-to-balloon time both directly and through improved pharmacology. The prevention of renal dysfunction during interventional studies remains of high interest in our field.
Let's start with the downside of DES. To reiterate, the biggest advance in the invasive treatment of coronary artery disease in the last decade is the drug-eluting stent. DES lowered the stent-related restenosis rate and remains highly effective for treating a variety of complex lesions. However, the downside ocontinue reading